Render Target: STATIC
Render Timestamp: 2024-11-21T13:14:49.587Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-26 17:16:13.120
Product last modified at: 2024-09-27T07:01:00.774Z
View Featured Offers >>
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72
  1. Products /
  2. Activators & Inhibitors /
  3. DL-α-Difluoromethylornithine Hydrochloride (DFMO)

DL-α-Difluoromethylornithine Hydrochloride (DFMO) #69294

    Product Information

    Product Usage Information

    DL-α-Difluoromethylornithine Hydrochloride (DFMO) is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 1 mg of powder in 0.42 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at room temperature, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 236.7 g/mol
    Purity >98%
    Molecular Formula C6H12F2N2 O2 • HCl • H2O
    CAS 96020-91-6
    Solubility Soluble in water at 25 mg/mL.

    Background

    The polyamine analog DL-α-Difluoromethylornithine Hydrochloride (DFMO) inhibits the enzyme ornithine decarboxylase (ODC), which catalyzes the rate-limiting step of polyamine biosynthesis. Originally developed to treat excessive hair growth and trypanosomiasis, DFMO was later studied as a potential therapeutic to block the development of cancers that relied on polyamine biosynthesis (1). Blocking polyamine biosynthesis with DFMO in conjunction with the drug-induced inhibition of polyamine uptake prevented or delayed tumor development in neuroblastoma-prone mice, and extended survival in rodent models of established tumors (2). Treatment with DFMO suppressed oncogene MYC expression and MYC-mediated tumorigenesis, and improved treatment of chemoresistant pancreatic ductal adenocarcinoma (3). Inhibition of ODC by DFMO blocked tumor growth in intact immunocompetent mice, but not in immunodeficient individuals. Specifically, DFMO promoted an immunological response to cancer as treatment of mice increased anti-tumor CD8+ T cell infiltration and IFN-γ production, augmented the efficacy of adoptive T cell therapy, and impaired myeloid-derived suppressor cell activity (4).

    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.